Grant: Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships
McMaster University
$105,000.00
Disarming the enemy: reversing antibiotic resistance with inhibitors of Vat enzymes
FY 2011-12
Summary
In 2011, it was estimated that at least 20 new antibiotic classes must reach the market within the next 50 years if modern healthcare is to keep pace with microbial drug resistance (1). In particular, the alarming rise of multi-drug resistant, Gram-positive pathogens has called into action streptogramin antibiotics. Streptogramin antibiotics are composed of two chemically-distinct groups (A and B), both of which are produced simultaneously by soil bacteria. Individually, both groups are bacteriostatic, but together, they are bactericidal. Streptogramins bind a unique site within the protein synthesizing machinery of pathogens, thereby blocking protein synthesis. Currently, streptogramins are used as drugs of last resort against serious infections. However, wide-spread resistance against streptogramins threatens their clinical use, as well as the outcomes of patients infected with resistant Gram-positive pathogens. Resistance against group A streptogramins is sufficient to inactivate streptogramin antibiotics entirely; of particular concern are Vat enzymes which inactivate group A streptogramins only. Therefore, we sought to identify novel inhibitors of Vat enzymes in order to reverse and characterize this resistance. Potent inhibitors were tested for pharmaceutical relevance and cytotoxicity. Further, the genetic and evolutionary controls of streptogramin production were investigated. Given the desperate need for novel antibiotics, this project will provide insight into microbial drug resistance, and aid in translational research where drug design is tailored specifically towards certain pathogens and the patients they infect.
(1) Coates et al. 2011. British J. Pharm. 163:184-194.
Department
Program
Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
257389
Name
Azad Marisa A
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Infection and Immunity
Theme2
Biomedical
Prcname2
Doctoral Research Awards - A
Projecttitle
Disarming the enemy: reversing antibiotic resistance with inhibitors of Vat enzymes
Programtype2
Studentship Programs
Orgnameinp2
McMaster University
Cihramount2
$105,000
Cihrequipment2
$0
Programname2
Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships
Keyworddelim
Bacterial Pathogenesis; Drug Design; Microbial Drug Resistance; Microbial Physiology; Protein Dynamics
Abstract
In 2011, it was estimated that at least 20 new antibiotic classes must reach the market within the next 50 years if modern healthcare is to keep pace with microbial drug resistance (1). In particular, the alarming rise of multi-drug resistant, Gram-positive pathogens has called into action streptogramin antibiotics. Streptogramin antibiotics are composed of two chemically-distinct groups (A and B), both of which are produced simultaneously by soil bacteria. Individually, both groups are bacteriostatic, but together, they are bactericidal. Streptogramins bind a unique site within the protein synthesizing machinery of pathogens, thereby blocking protein synthesis. Currently, streptogramins are used as drugs of last resort against serious infections. However, wide-spread resistance against streptogramins threatens their clinical use, as well as the outcomes of patients infected with resistant Gram-positive pathogens. Resistance against group A streptogramins is sufficient to inactivate streptogramin antibiotics entirely; of particular concern are Vat enzymes which inactivate group A streptogramins only. Therefore, we sought to identify novel inhibitors of Vat enzymes in order to reverse and characterize this resistance. Potent inhibitors were tested for pharmaceutical relevance and cytotoxicity. Further, the genetic and evolutionary controls of streptogramin production were investigated. Given the desperate need for novel antibiotics, this project will provide insight into microbial drug resistance, and aid in translational research where drug design is tailored specifically towards certain pathogens and the patients they infect.
(1) Coates et al. 2011. British J. Pharm. 163:184-194.
Competitiondate
201110
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Azad, Marisa A
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $105,000~ $0~